- DSUVIA™ (sufentanil sublingual tablet, 30 mcg) New Drug Application (NDA) resubmitted to U.S. Food and Drug Administration (FDA)
- March 31, 2018 cash and short-term investments balance of $51.2 million
- Combined R&D and G&A expenses declined 32% from Q1 2017, conserving cash for anticipated DSUVIA launch, if approved
PR Newswire
REDWOOD CITY, Calif., May 9, 2018